Epigenetic regulation of fibrocyte differentiation?

Journal of Molecular and Cellular Cardiology

Volumn 69, Issue , 2014, Pages 85-87

  Lishnevsky, Marta ^a   Haudek, Sandra B ^a  

^a HOUSTON METHODIST HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN II; COLLAGEN; CONNEXIN 40; CYCLIN DEPENDENT KINASE INHIBITOR 1C; DNA; HISTONE ACETYLTRANSFERASE; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; KRUPPEL LIKE FACTOR 4; MONOCYTE CHEMOTACTIC PROTEIN 1; MYOCYTE ENHANCER FACTOR 2; PROTEIN P15; SIRTUIN; TRANSFORMING GROWTH FACTOR BETA;

AUTOPHAGY; BONE MARROW; CELL CYCLE REGULATION; CELL DEATH; CELL DIFFERENTIATION; CELL INFILTRATION; CELL MATURATION; CELL MIGRATION; CELL PROLIFERATION; CELL TYPE; CELLULAR DISTRIBUTION; CELLULAR SECRETION; DIASTOLIC DYSFUNCTION; DNA TRANSCRIPTION; DRUG ACTIVITY; DRUG TARGETING; EDITORIAL; ENZYME INHIBITION; EPIGENETICS; FIBROBLAST; FIBROCYTE; GENE TARGETING; GENETIC REGULATION; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; HEART VENTRICLE FAILURE; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE REMODELING; HISTONE ACETYLATION; HUMAN; IN VITRO STUDY; INFLAMMATION; MONONUCLEAR CELL; MYOFIBROBLAST; NUCLEOSOME; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN LOCALIZATION; PROTEIN SECRETION; PROTEIN SYNTHESIS; PROTEIN TRANSPORT; STEM CELL; UPREGULATION; ANIMAL; DRUG EFFECTS; FIBROSIS; MALE; METABOLISM;

ANGIOTENSIN II; ANIMALS; FIBROBLASTS; FIBROSIS; HISTONE DEACETYLASE INHIBITORS; HUMANS; MALE;

EID: 84895464034     PISSN: 00222828     EISSN: 10958584     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2014.01.019     Document Type: Editorial

References (25)

1. Burlew B.S., Weber K.T. Cardiac fibrosis as a cause of diastolic dysfunction. Herz 2002, 27:92-98.
2. Frangogiannis N.G. Chemokines in the ischemic myocardium: from inflammation to fibrosis. Inflamm Res 2004, 53:585-595.
3. Kania G., Blyszczuk P., Eriksson U. Mechanisms of cardiac fibrosis in inflammatory heart disease. Trends Cardiovasc Med 2009, 19:247-252.
4. Porter K.E., Turner N.A. Cardiac fibroblasts: at the heart of myocardial remodeling. Pharmacol Ther 2009, 123:255-278.
5. Duffield J.S., Lupher M., Thannickal V.J., Wynn T.A. Host responses in tissue repair and fibrosis. Annu Rev Pathol 2013, 8:241-276.
6. Haudek S.B., Xia Y., Huebener P., Lee J.M., Carlson S., Crawford J.R., et al. Bone marrow-derived fibroblast precursors mediate ischemic cardiomyopathy in mice. Proc Natl Acad Sci U S A 2006, 103:18284-18289.
7. Sopel M., Falkenham A., Oxner A., Ma I., Lee T.D., Legare J.F. Fibroblast progenitor cells are recruited into the myocardium prior to the development of myocardial fibrosis. Int J Exp Pathol 2012, 93:115-124.
8. Ren J., Yang M., Qi G., Zheng J., Jia L., Cheng J., et al. Proinflammatory protein CARD9 is essential for infiltration of monocytic fibroblast precursors and cardiac fibrosis caused by Angiotensin II infusion. Am J Hypertens 2011, 24:701-707.
9. Bucala R., Spiegel L.A., Chesney J., Hogan M., Cerami A. Circulating fibrocytes define a new leukocyte subpopulation that mediates tissue repair. Mol Med 1994, 1:71-81.
10. Peng H., Herzog E.L. Fibrocytes: emerging effector cells in chronic inflammation. Curr Opin Pharmacol 2012, 12:491-496.
11. Galligan C.L., Fish E.N. The role of circulating fibrocytes in inflammation and autoimmunity. J Leukoc Biol 2013, 93:45-50.
12. Williams S.M., Golden-Mason L., Ferguson B.S., Schuetze K.B., Cavasin M.A., Demos-Davies K., et al. Class I HDACs regulate angiotensin II-dependent cardiac fibrosis via fibroblasts and circulating fibrocytes. J Mol Cell Cardiol 2013, 67C:112-125.
13. Luger K., Mader A.W., Richmond R.K., Sargent D.F., Richmond T.J. Crystal structure of the nucleosome core particle at 2.8 A resolution. Nature 1997, 389:251-260.
14. Bannister A.J., Kouzarides T. Regulation of chromatin by histone modifications. Cell Res 2011, 21:381-395.
15. de Ruijter A.J., van Gennip A.H., Caron H.N., Kemp S., van Kuilenburg A.B. Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem J 2003, 370:737-749.
16. Peserico A., Simone C. Physical and functional HAT/HDAC interplay regulates protein acetylation balance. J Biomed Biotechnol 2011, 2011:371832.
17. Yang X.J., Seto E. Lysine acetylation: codified crosstalk with other posttranslational modifications. Mol Cell 2008, 31:449-461.
18. McKinsey T.A. Targeting inflammation in heart failure with histone deacetylase inhibitors. Mol Med 2011, 17:434-441.
19. Pang M., Zhuang S. Histone deacetylase: a potential therapeutic target for fibrotic disorders. J Pharmacol Exp Ther 2010, 335:266-272.
20. Bojang P., Ramos K.S. The promise and failures of epigenetic therapies for cancer treatment. Cancer Treat Rev 2014, 40:153-169.
21. Tao H., Shi K.H., Yang J.J., Huang C., Zhan H.Y., Li J. Histone deacetylases in cardiac fibrosis: current perspectives for therapy. Cell Signal 2013, 26:521-527.
22. Xie M., Hill J.A. HDAC-dependent ventricular remodeling. Trends Cardiovasc Med 2013, 23:229-235.
23. Kee H.J., Kook H. Roles and targets of class I and IIa histone deacetylases in cardiac hypertrophy. J Biomed Biotechnol 2011, 2011:928326.
24. Haudek S.B., Cheng J., Du J., Wang Y., Hermosillo-Rodriguez J., Trial J., et al. Monocytic fibroblast precursors mediate fibrosis in angiotensin-II-induced cardiac hypertrophy. J Mol Cell Cardiol 2010, 49:499-507.
25. Shao D.D., Suresh R., Vakil V., Gomer R.H., Pilling D. Pivotal advance: Th-1 cytokines inhibit, and Th-2 cytokines promote fibrocyte differentiation. J Leukoc Biol 2008, 83:1323-1333.